How would you treat a patient with progressive ALK (+) NSCLC that has MET Exon 14 deletion upon repeat molecular testing on metastatic site?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

What would your approach be to treatment in a patient with stage IV thymic squamous cell carcinoma who received neoadjuvant carboplatin, paclitaxel, and ramucirumab and underwent R1 resection?

How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?

For a patient with intracranial mets for ES-SCLC who undergoes resection, do you routinely offer post-op SRS to the cavity, or do you proceed with WBRT?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.